Related Experiment Video

Updated: Jun 26, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

ADAM33 genetic polymorphisms and risk of atopic dermatitis among Japanese children

Aya Matsusue1, Chikako Kiyohara, Keiko Tanaka

  • 1Department of Forensic Medicine, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, Japan.

Clinical Biochemistry
|January 17, 2009
PubMed

Insights

The ADAM33 gene polymorphism rs2853209 is associated with a reduced risk of atopic dermatitis (AD) in Japanese children. This finding suggests a potential genetic link between ADAM33 and AD development.

Area of Science:

  • Genetics
  • Dermatology
  • Immunology

Background:

  • ADAM33 is a known asthma susceptibility gene.
  • Understanding genetic factors in atopic dermatitis (AD) is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the association between ADAM33 gene single nucleotide polymorphisms (SNPs) and atopic dermatitis (AD) in Japanese children.
  • To explore the potential role of ADAM33 in the pathogenesis of AD.

Main Methods:

  • A case-control study was conducted with 140 AD cases and 258 controls.
  • Seven specific SNPs of the ADAM33 gene were analyzed.
  • Genotyping was performed to identify associations between SNPs and AD risk.

Main Results:

  • The SNP rs2853209 (T>A) showed a significant association with reduced AD risk.
  • Individuals with the AA genotype for rs2853209 had a lower risk of AD (OR=0.55).
  • A haplotype containing the rs2853209 A allele was significantly associated with decreased AD risk (OR=0.26).

Conclusions:

  • This study provides initial evidence for an association between ADAM33 gene polymorphism and atopic dermatitis risk in Japanese children.
  • The findings suggest that specific ADAM33 variants may confer protection against AD.
  • Further research with larger sample sizes is needed to confirm these results and elucidate the underlying mechanisms.
Abstract

More Related Videos

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format05:58

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

Published on: August 20, 2018

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Incomplete Dominance01:43

Incomplete Dominance

Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.